BioPharmSignal logoBioPharmSignal

Biotech News

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

Taysha Gene Therapies (TSHA)Taysha Gene TherapiesEarnings

DALLAS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today

Related news

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

TSHATaysha Gene Therapies2026-10-01 12:00 EST

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

NBIXNeurocrine Biosciences2026-10-12 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

CGTXCognition Therapeutics2026-11-02 12:30 EST

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

TEVATeva Pharmaceutical Industries2026-09-23 20:45 EST

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

SANASana Biotechnology2026-11-05 21:05 EST

Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates

SRPTSarepta Therapeutics2026-11-05 21:05 EST

Sarepta Therapeutics Announces Third Quarter 2026 Financial Results and Recent Corporate Developments

NTLAIntellia2026-11-05 13:00 EST

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates

CRSPCRISPR Therapeutics2026-11-02 21:01 EST

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-10-27 20:01 EST

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

View all latest news

Taysha Gene Therapies

CNS Gene Therapy Focus Taysha Gene Therapies develops adeno-associated virus gene therapies for severe monogenic diseases of the central nervous system. Its strategy centers on one-time treatments intended to address the underlying genetic cause of disease. Lead Rett Syndrome Program TSHA-102 is an intrathecally delivered AAV9 gene...

Recent company news

TSHATaysha Gene Therapies2026-11-06 13:00 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

TSHATaysha Gene Therapies2026-10-02 12:00 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TSHATaysha Gene Therapies2026-10-01 12:00 EST

Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting

TSHATaysha Gene Therapies2026-09-04 12:00 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
4.09 USD
Market cap
1.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States